This Stock Has 5X Potential (+Major Catalyst)

Folks, this $22 stock has 5x potential. Now, I know that sounds like a big claim, but context. Back on February 16th, I made a video breaking down why I believed Tims was screaming buy at those current prices, and the stock had been absolutely crushed. We're talking about a company doing nearly $2. 5 billion in revenue, growing like crazy, actually profitable, and the market was pricing it like it was going bankrupt. I laid out why I thought the bare case was wildly overdone. And today, well, they had a massive win that takes my thesis to a whole other level. Now, why do I believe there's so much upside? Well, for starters, HIMS just resolved its single biggest overhang in one move, and the market hasn't fully priced it in yet. B, this deal doesn't just eliminate risk, it actually expands HIM's total addressable market size dramatically. C, the fundamentals were already insane before today. 2. 35 billion in revenue, profitable, growing 59% year-over-year. And the stock was priced as if it was a dying company. and the short sellers wanted you to think that if you held that you were the biggest since the invention of morons. And then D, this company's got a global expansion story that just absolutely kicked into overdrive. In today's video, I'm going to break down exactly what just happened, why this changes everything about the long-term thesis and why I think there's massive opportunity for long-term holders in this stock. Even with today's massive move, the stock is still it's still trading at distressed apocalyptic prices relative to what I believe this business is actually worth. And that in my opinion is an opportunity. And I'll present my case for it and of course let you be the judge. And then at the end of the video, it's going to be time for our sponsored segment on Norex, ticker symbol KNRX on the NYC American. This is an AIdriven adtech company that built a single platform to manage every digital advertising channel in one place. We're talking about one unified system to run Google Meta, LinkedIn, Tik Tok, programmatic, display, and more. Powered by an AI agent that optimizes across all of it in real time. This is a company positioning itself as the infrastructure layer for the next generation of digital advertising. And they just launched something that's getting attention from the agenic AI world. I'll break down the company and why you may want to begin your research on it and do your due diligence. And as always, if you're the one taking the ultimate risk, you got to be the one doing the ultimate risk. Always do your own due diligence on all ideas presented. Okay, first we need to start with a recap of what HIMS actually does. So HIMS and Hers Health, ticker symbol HIMS, is a direct to consumer telealth platform that connects patients with licensed healthcare providers entirely online. No insurance, no waiting rooms, no pharmacy lines. Founded in 2017, the company built its brand around treating conditions people historically found embarrassing or inconvenient to address in person, ed hair loss, skincare, and mental health. Over time, it expanded into women's health under the HERS brand, and more recently into weight loss, hormone therapy, diagnostics, and longevity. The model is subscription-based. Patients basically pay a monthly fee, get access to a provider, receive a prescription, and have their medication shipped directly to the door. With over 2. 5 million active subscribers and 2. 35 billion in 2025 revenue grown 59% year-over-year, this is indeed a scaled profitable consumer health business that the market has been treating like a dying one. Now, you have to understand this company has largely been beaten down on the crisis narrative around their weight loss segment. Almost their entire beatdown was driven by this one product line. Him's explosive growth over the past years was largely fueled by compounded semi-glutide, a copycat version of Novodoris Disk's Wiggoi, which they could legally sell while the drug was listed in shortage by the FDA. The business exploded, but it put a giant target on their back. Novo sued for patent infringement. The FDA declared the shortage over and cracked down on compounders, and the DOJ got looped in. The stock fell over 75% from its highs as Wall Street priced in an existential threat to the entire company. However, much of this just completely flipped and that's why the stock price absolutely exploded today. However, this again is very little compared to how much the stock has gone down and that's why I believe the bullcase for long-term holders is still very much intact. So, what just happened? and Lenovo Nordisk, the maker of Ozmpic and Wegoi, the most popular GLP1 weight loss drugs on the planet, just announced they are dropping, yes, dropping their lawsuit against him and hers. And not only that, they've agreed to actually partner with HIMS, bringing OPIC and WGOI directly onto the HIMS platform. So, let me repeat that. The company that was suing HIMS into oblivion just became their business partner. And again, if you look back at what the short sellers were saying, they were saying that HIMS was going to be destroyed, absolutely obliterated by these lawsuits just a few weeks after they told everybody to get out of their positions. Well, guess what? The short sellers have been proven wrong and HIMS is partnering with this company. The bare case on this stock that led to short sellers aggressively shorting it and analysts across the board lowering and lowering and completely cratering their price targets was the idea that HIMS was basically just a GLP-1 business and that GLP-1 business was over. Not only was that not correct even before this lawsuit was dropped, but now it's especially not correct. That bear case is now dead. Under this new agreement, HIMS will carry Ompic and Wiggoi injections and Wiggoi oral pills directly on its platform. Full suite. Novo drops the lawsuit entirely. The FDA commissioner himself praised the deal publicly and HIMS transitions from

scrappy compounding disruptor to authorized distributor for the world's most popular weight loss drug. Big win for all parties involved here. If you've been following closely, you understand that the compounded semi-glutide that was selling was high margin specifically because when you have in-house distribution versus branded distribution, it's easier to have much higher margins. So, is this even that much of a net positive? Well, yes, it's a huge net positive. This is how I would frame the situation. Firstly, the legal overhang was the entire bare case. Full stop. Every analyst who cut their price target, every short seller loading up on puts, the core argument was regulatory and legal risk. The DOJ referral, the patent lawsuit, the FDA crackdown today, all of that risk evaporated in a single press release. The FDA commissioner came out and praised the deal. You cannot get more regulatory green light than that. Secondly, think about what HIMS actually is. At its core, HIMS is not a drug company. It's a subscriber platform, a distribution engine, a consumer health brand. They have 2. 5 million people who trust them to manage their healthcare online. They have a best-in-class tellahalth experience, a seamless pharmacy fulfillment operation, and a brand that resonates with consumers in a way that no traditional pharmacy has been able to replicate. What they were missing in the GLP1 space for their growth was legitimacy and a sustainable supply chain. They now have those things. That's exactly what this Novo deal provides. And now they're not selling the knockoffs. They're selling the real thing at competitive prices to their existing base and to a massive new audience who would have never touched a compounded product because they don't trust it without the brand name. Third, this actually strengthens their competitive moat. Novo Nordisk is not going to partner with every teleahalth company that knocks on their door. Hims is now an authorized endorsed distribution channel for the world's dominant GLP-1 franchise. That is a genuine competitive advantage. And it's one that you got to pay attention to. And it's one that took years of subscriber growth, brand building, and frankly, lots and lots of money and years of doing these different types of distributions and unbranded deals to actually build. And here's another angle. Eli Lily is expected to launch their oral weight loss pill or for Glyon in the second quarter pending FDA approval. HIMS management has already said they're in active conversations with anyone who can bring new therapies to the platform. Think about what that means. Hims could end up as the preferred consumer distribution channel for both GLP1 franchises. Ompic and Rioi from Novo or Legolafron from Lily, both sold through one platform. For a company that analysts and short sellers across the board basically declared dead and said they'd never operate in the weight loss space or hell any space ever again. Well, this company's doing pretty damn good now. Even before all of this, the fundamentals were ridiculous. And I mean ridiculously good. Hims reported full year 2025 results just a few weeks ago. Revenue 2. 35 billion up 59% year-over-year. Net income $128 million adjusted EBATA 318 million over $2. 5 million subscribers over a billion dollars in cash. A 59% revenue growth company profitable generating over $300 million in Ibata. And before today's rally, it was trading at just roughly four to five times Ibata, which again we said just a few weeks ago was an insane opportunity. You have to understand that when you're looking at a company, you have to actually value it not based on the stock price. You have to value it on the company and what the company's doing. Now, yes, the GLP-1 transition does create some margin pressure. Of course, it does because you're not doing in-house anymore. You're going to brand it. However, I think net in effect, this is great for the brand long-term, and it's many, many, many multiples better than what the stock is pricing in, which was a complete destruction of their entire weight loss business. Which, by the way, even if this lawsuit hadn't been dropped, will they still add other weight loss products? This new news is going to allow him to remonetize their massive dedicated subscriber base. And the long-term revenue potential is arguably much larger now because branded Wiggoi and Zepic reach a much broader market than Compounded ever could. Okay. Next, there's some other news that has nothing to do with this Novo deal. So, 3 weeks ago, HIMS announced they're acquiring Eucalyptus. Now, if you haven't heard of Eucalyptus, that's kind of the point. It's not a well-known name in the US, but Eucalyptus is a leading consumer digital health platform operating in Australia, the UK, and Germany with expanding operations in Japan and Canada. Himsa has been growing in the US and a handful of European markets. But the Eucalyptus acquisition essentially turbocharges their global footprint in one move. They are doing this international expansion at the same time, simultaneously with cleaning up their US regulatory situation. The long-term vision that management has been articulating is becoming the largest global consumer health platform in the world with today's Novo deal and the eucalyptus acquisition clos in midyear. Well, that vision has a ton of credibility. Okay, now I need to take a minute to reflect on our Discord alert. So, so on February 17th, I posted a full options alert in the Zip Trader Plus Discord. The trade him $20 strike calls expiring July 17th, 2026. Now, here was the logic at that time. The stock was down 77% from its highs. It was trading at just 1. 6 6 times Ford sales with 1. 1 billion in cash on the balance sheet. The average analyst price target was around $33, nearly double where the stock was sitting and the July expiry was deliberate. It captured two earning cycles, the February 23rd print and the May quarter, plus gave enough runway for the legal situation to get clarity one way or the other. The core bet was simple. The market was massively overpriced in the GLP1 disaster scenario

if survived that regulatory pressure, which I believed it would. Well, the stock had no business being where it was and the calls had explosive potential. Now, I was also very explicit about the risks, which you got to be. This was a high-risisk, high conviction idea. Beta was nearly five. Ivy through the roof. Goldman's price target at the time was literally the strike price. But the thesis played out this morning. Hims gapped up over 40% and blew right through that $20 strike price. These calls went from out of the money to in the money in a single session. Now, if you played these or you played other similar calls, congratulations. These weren't easy ones. Again, HIMS was a thesis play based on the actual value of the company, not based on where the market had dysphorically made it trade. The people that do the best over the medium to long term especially are the ones that can actually sort through the noise and not focus on the noise itself. It's great to ride the emotions of a stock, but it's not so great to use the emotions of a stock to value whether or not you should be in a position because quite frankly, emotions are volatile. Again, one of the biggest things that you need to understand is that a stock and a company are two absolutely different things. Always look at the company first. Value the company and then look at the stock price and see if there's a disconnect. Because if there's a massive disconnect, that means buying opportunity. And if there's a big disconnect and the price is overvalued, well, that means big selling, locking in the profit opportunity. This game cuts both ways and that's a great thing because that means that you can get better deals than ever, sell out when it's not really such a good deal anymore. So anyways, bigger picture of the HIMS case today is much stronger than it's been in a very long time. And I think our long-term thesis is way more backed by evidence than it was just a few weeks ago. And I think I made a convincing case just a few weeks ago. Anyways, let us know your take on him down below. And let's move on to our sponsored segment. And now it's time for our sponsored segment on Norex, ticker symbol KN&RX on the NYC American, an AIdriven programmatic advertising company that is operating in a genuinely interesting corner of the market right now. I'm talking about the infrastructure problem at the heart of digital advertising. The problem that nobody talks about, but every marketer lives with every single day. But this is not just a product story. This is about fixing a broken operating model inside a $740 billion industry and one that's only getting more complex as AI rewrites the rules. Let me give you some context here. So why is there a massive unmet need in the space? Well, the average enterprise marketing team manages five or more separate ad platforms. Google, Meta, LinkedIn, Tik Tok, CTV, programmatic, each with its own API, its own reporting logic, its own optimization algorithm, and its own data silo. There is no unified picture of what is actually working. AI is accelerating the complexity problem. The shift towards agenic AI, autonomous systems that make decisions and take action without human input at every step is real and it's happening fast. But agentic AI cannot work across five disconnected platforms. It needs unified infrastructure. And right now, for most marketers, that infrastructure just doesn't exist. Combined, these dynamics mean brands are spending against a $740 billion digital ad market while running on a fundamentally fragmented, inefficient operating model with no dominant platform solving it. The waste is structural and it's substantial. The inefficiency is industrywide. Now, you might be thinking, Charlie, why can't you just hire an agency to manage all of this? Well, fair question. Agencies help, but they introduce their own problems. They work across platforms with preferred partnerships that may not align with your best interests. They charge a percentage of media spend, which means their incentives aren't always aligned with efficiency, and they abstract you from your own data. The agency model was designed for a world with a handful of channels. That world is gone. That's the setup, and that's where Norex comes in. So, what exactly is Norex building, Charlie? Well, their approach is different from conventional ad tech. They're not building another point solution that bolts onto your existing stack. They're replacing the stack entirely with one AI powered platform that runs everything from a single interface. Two core pillars, one massive market opportunity. Now, here's what they built. Pillar one, the Norex XPO platform. So XPO is Norex's flagship platform. The goal, give marketers a single cloud-based system to plan, execute, and optimize campaigns across every major digital channel. Search, social, programmatic, CTV, OTT, video, audio, display, native, and digital out of home without switching between platforms, reconciling conflicting data, or managing five separate agency relationships. At the core of XPO is Norex's proprietary AI engine called Chyros. This is the competitive mode. Kyros handles real time optimization across all channels simultaneously continuously adjusting audience targeting bid strategies and budget allocation based on live performance data not weekly reports real time and the results are being validated in the market one of Canada's largest dental care networks 450 plus clinic locations deployed XPO and delivered a 7% lift in new patient acquisition 10% revenue growth and a 20% reduction in total marketing costs according to the company a nationwide US consumer litigation campaign achieved 29% reduction in cost per acquisition, optimizing for signed legal retainers, not clicks. A major automotive platform used XPO to convert national digital awareness campaigns into track dealership visits at scale. These are real enterprise clients, real measurable outcomes in high stakes verticals where performance accountability matters. Pillar two, the Aenic AI ready ads API. So in February of 2026, Norex launched something that positions them directly in the agentic AI conversation. The Norex ads API

purpose-built as infrastructure for AI native advertising workflows. And here's why that matters. Aenic AI systems need a single programmable entry point to act across platforms. They can't operate across five disconnected APIs. Norex's ads API gives them exactly that. one interface to manage Google ads, meta, LinkedIn, Tik Tok and programmatic via natural language prompts through a connection with Amazon ads MCP server. The API also connects the advertising common protocol ADCP an open standard designed to unify ad platforms under a single interface. Now, of course, I want to remind you this is a micro cap and micro caps are incredibly risky. Company is not yet profitable. It's in the early stages of investing in itself. And if you know anything about micro caps, you know that capital will likely be needed to fund future growth initiatives, which means there is delilution risk. There's also thin liquidity, meaningful volatility. And that's the deal with stocks at this size. But the overall story with Norex is this. They've built a differentiated platform solving a real structural problem inside a $740 billion market that's only getting more complex. XPO is live, generating revenue, and producing measurable outcomes for enterprise clients across healthcare, legal, and automotive. The Chyros AI engine gives them a real-time optimization layer that point solutions can't replicate. The new Aenic AI ready ads API positions them directly in the path of where enterprise advertising infrastructure is going. One programmable interface for AI agents to manage every major channel simultaneously. And their white label deployment embedding XPO inside a live commerce platform is an early proof of concept for XPO as infrastructure that can be licensed into thirdparty ecosystems, not just sold. Anyways, if you'd like to learn more, I'll put the link to their investor relations page down below. Read through their SEC filings, do all of your own due diligence, and come to your own conclusion. Have a great rest of your day.